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Introduction {#sec001}
============

Human dental pulp stem cells exhibit high proliferation, greater tissue regeneration capabilities, lower immunogenicity, and greater plasticity than those of other mesoderm-derived mesenchymal stem cells \[[@pone.0229996.ref001]\]. Furthermore, unlike other mesoderm-derived mesenchymal stem cells, human dental pulp stem cells are isolated easily from extracted teeth without causing secondary damage or ethical controversy. Paino et al. have reported that human dental pulp stem cells are a good option for applications in human bone tissue engineering without the use of scaffolds in vitro and in vivo \[[@pone.0229996.ref002]\]. Therefore, human dental pulp stem cells have attracted attention as candidate cells for stem cell therapy for various disorders, including the regeneration of lost pulp and dentin in the root canal space \[[@pone.0229996.ref003],[@pone.0229996.ref004]\]. Recently, a pilot clinical study and a phase I clinical trial in humans have been reported that demonstrated that autologous transplantation of mobilized dental pulp stem cells is a safe and efficient therapeutic approach \[[@pone.0229996.ref005]--[@pone.0229996.ref007]\]. However, there are some limitations to this approach, such as the high cost of the safety and quality control tests for isolated individual dental pulp cell products before transplantation. Therefore, more effective tools are needed to provide low cost and high reliability for stem cell-mediated regeneration therapy of lost pulp.

Our research group has previously reported efficient immortalization in multiple species via co-expression of R24C mutant cyclin-dependent kinase 4 (CDK4^R24C^), Cyclin D1, and telomere reverse transcriptase (TERT) \[[@pone.0229996.ref008]--[@pone.0229996.ref014]\]. This immortalization method using mutant CD[K4]{.ul}, Cyclin [D]{.ul}1, and [T]{.ul}ERT was termed \"K4DT\" in reference to the introduced genes. The chromosomal pattern of cells established using the K4DT method is retained, along with the nature of primary cells, possibly due to the intact function of p53 \[[@pone.0229996.ref013],[@pone.0229996.ref015]--[@pone.0229996.ref017]\]. We also recently demonstrated that our corneal epithelial cell line, established with the K4DT immortalization method, can be a useful tool to detect eye toxicity, and it can be used as a new resource for *in vitro* ocular toxicity testing \[[@pone.0229996.ref018]\]. These findings indicated that applying the K4DT immortalization method to human dental pulp stem cells might be useful in generating a more effective tool to evaluate the safety and quality of isolated individual dental pulp cell products before transplantation. We speculated that *in vitro* culturing of human dental pulp stem cells immortalized by the K4DT method might be useful as a biological resource to reduce the cost of pulp regeneration therapy.

With this aim in mind, we transduced CDK4^R24C^, Cyclin D1, and TERT into human dental pulp stem cells via retrovirus. We successfully established immortalized human dental pulp stem cells and evaluated the characteristics of the cells.

Materials and Methods {#sec002}
=====================

Cell Culture {#sec003}
------------

Human dental pulp stem cells (PT-5025) were purchased from Lonza Japan Ltd (Tokyo, Japan) and were cultured according to the manufacturer's instructions.

Preparation and infection of recombinant retroviruses into human dental pulp stem cells {#sec004}
---------------------------------------------------------------------------------------

To immortalize primary human dental pulp stem cells, we prepared recombinant retroviruses expressing R24C mutant cyclin-dependent kinase 4 (CDK4^R24C^), Cyclin D1, and TERT. PQCXIP-CDK4R24C (puromycin-resistant), pQCXIN-Cyclin D1 (G418-resistant), and pCLXSH-TERT (hygromycin B-resistant) retroviral plasmids as well as pQCXIN-EGFP (G418-resistant) as a control expressing EGFP to monitor the efficiency of infection were constructed as described previously \[[@pone.0229996.ref016]\]. These retroviral plasmids were co-transfected into 293T cells together with packaging plasmids, pCL-GagPol and pCMV-VSV-G-RSV-Rev, by using the lipofection method \[[@pone.0229996.ref019]\]. Viral fluids recovered from the transfected cells were filtered through 0.45 μm disks (Sartorius, Goettingen, Germany; product code, 17598 K). Primary human dental pulp stem cells were inoculated with individual or mixed recombinant viruses in the presence of 8 μg/mL of polybrene (hexadimethrine bromide, Sigma-Aldrich, \#H9268). The cell culture medium was replaced with fresh medium one day post-inoculation followed by selection with 1 mg/mL G418, 0.8 μg/mL puromycin and/or 40 μg/mL hygromycin according to drug resistance of each vector and its combination. One week post-selection, the obtained resistant cells were expanded into new plates. We named the retrovirus-infected human dental pulp cells WT (no treatment), EGFP (infected with EGFP-expressing retrovirus), K4D (infected with mutant CD[K4]{.ul} and Cyclin [D]{.ul}1), TERT (infected with TERT), and K4DT (infected with mutant CD[K4]{.ul}, Cyclin [D]{.ul}1, and [T]{.ul}ERT) cells according to the introduced genes. The infected mass population of cells was subjected to further analysis, such as western blotting and extension of the life span.

Population doublings {#sec005}
--------------------

To measure the cell proliferation rates of WT, K4D, and K4DT cells, we sequentially passaged the cells. All of the cell lines were cultured in DMEM with 10% FBS containing penicillin/streptomycin. Each cell line was initially seeded into 6-well plates at a density of 5.0 × 10^4^ cells in triplicate. When the cell line reached confluency, the cells were dispersed using 0.05% trypsin-EDTA (Life Technologies). We recorded the total number of cells in each dish using an automatic cell counter (Thermo Fisher Scientific, Waltham, MA, USA). Cells (5.0 × 10^4^) were then seeded into a new dish to evaluate their growth rate by determining the population doubling level (PDL). The PDL was calculated using the following equation: PDL = log2 (A/B), where A is the number of cells harvested at each passage and B is the number of seeded cells.

Western blotting {#sec006}
----------------

To extract proteins from WT, K4D, and K4DT cells, we lysed cells in a buffer containing 50 mM Tris--HCl (pH 7.4), 0.15 M NaCl, 1% Triton X-100, 2.5 mg/mL sodium deoxycholate (Wako, Osaka, Japan), and a protease inhibitor cocktail (1/200 dilution, Nacalai Tesque). Total cell lysates were separated by SDS-PAGE and then transferred to PVDF membranes (Merck, Darmstadt, Germany). After the membranes were blocked with 1% nonfat dry milk with 0.05% Tween 20, they were probed with mouse anti-human CDK4 (1:2500, \#sc-56277; Santa Cruz Biotechnology, Dallas, TX, USA), Cyclin D1 (1:5000, \#553; MBL, Nagoya, Japan), and α-tubulin (1:1000, \#sc-32293; Santa Cruz Biotechnology) antibodies. HRP-conjugated goat anti-mouse IgG (1:2000, \#330; MBL) or HRP-conjugated goat anti-rabbit IgG (1:2000, \#458; MBL) was used as a secondary antibody. Immunoreactive signals were detected using an Image Quant LAS-4000 mini system (GE Healthcare, Little Chalfont, UK) with Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific).

Genomic polymerase chain reaction {#sec007}
---------------------------------

Genomic DNA was extracted using a NucleoSpin Tissue kit (TaKaRa Bio, Shiga, Japan) according to the manufacturer\'s protocol. PCR amplification was performed using Go Taq Green Master Mix (Promega, Madison, USA) based on the protocol provided by the manufacturer (2 min of pre-denaturation at 95°C, 30 cycles of 15 sec at 95°C, 15 sec at 55°C, and 1 min at 72°C). For the detection of the *Cyclin D1* cassette, the R24C mutant *CDK4* cassette, and the *TERT* cassette, the PCR primer sequences used were described in our previous publication \[[@pone.0229996.ref014]\]. Tuberous sclerosis type II (TSC2) was used as an internal control since the TSC2 gene is a unique gene in the human genome, and furthermore there are no TSC2 pseudogenes. For internal control of genomic amplification, we designed forward and reverse primers for TSC2, (5\'-ACT AGG CAG CAA CCA GCG TCAC -3\') and (5\'- TGG ACC CCA TCT CGG CACCA-3\'), respectively. PCR products were separated by 1% agarose gel electrophoresis and stained with ethidium bromide.

Cell cycle assay {#sec008}
----------------

The cell cycle phase was analyzed using a Muse Cell Cycle Assay Kit (\#MCH100106; Merck) and Muse Cell Analyzer (\#0500--3115; Merck). The detailed method for the analysis was based on the protocol provided by the manufacturer. Statistical significance was evaluated using a non-parametric Steel-Dwass test with six samples for each experimental group.

Senescence-associated β-galactosidase staining {#sec009}
----------------------------------------------

At passage 7, WT, K4D, and K4DT cells were seeded at a density of 5.0 x 10^4^ cells/well in 6-well plates. After 4 days of culture, they were fixed and stained using a Senescence Detection Kit (\#K320-250; Biovision, Inc., Milpitas, CA, USA) according to the manufacturer's protocol.

Karyotype analysis {#sec010}
------------------

Karyotype analyses were carried out in the K4DT cells. Standard G-banding chromosome analysis was performed in the Nihon Gene Research Laboratories, Inc. (Sendai, Japan). The chromosome number was determined from 50 mitotic cells, and the detailed chromosomal condition was evaluated using G-banding in 20 mitotic cells.

Flow cytometric analysis {#sec011}
------------------------

Cells (1.0 × 10^6^ cells) were suspended in PBS containing 2% FBS and 2 mM EDTA, and stained with FITC conjugated antibodies against human CD90, CD45, and CD34 (BioLegend, San Diego, CA, USA) to characterize the K4DT cells compared with the WT cells. FITC mouse IgG1, κ Isotype control antibody and FITC mouse IgG2a, κ Isotype control antibody (BioLegend, San Diego, CA, USA) were used for the negative control experiments. Data were analyzed with a CytoFlex flow cytometry system (Beckman Coulter, Brea, CA, USA).

The inductions and detections of osteogenic or adipogenic differentiation {#sec012}
-------------------------------------------------------------------------

To induce osteogenic differentiation, confluent cells were incubated in osteogenic induction medium consisting of MEM alpha (Thermo Fisher, 32571036) supplemented with 10% FBS, 0.01 μM dexamethasone (Sigma, D4902), 6 mM β-glycerol phosphate (Sigma, G9422), and 50 μg/ml ascorbic acid (Sigma, A7506) for 2--4 weeks. The induction medium was changed every 3 days. Bone matrix mineralization was assessed by staining using a calcified nodule staining kit with Alizarin red S (Cosmo Bio, Tokyo, Japan) according to the manufacturers' protocols. For the detection of osteogenic differentiation, we performed immunofluorescence staining with an antibody against osteocalcin (Santa Cruz, sc-390877). Primary antibodies were detected by Alexa568 (ThermoFisher Scientific) conjugated secondary antibody. Nuclear staining was performed with DAPI. Fluorescence images were obtained using a fluorescence microscope, BZ-X810 (Keyence, Osaka, Japan). To induce adipogenic differentiation, cells were cultured to 80% confluence and cultured in adipogenic induction medium consisting of high glucose DMEM (Wako) supplemented with 10% FBS, 10 μg/ml insulin (Sigma, I9278), 1 μM dexamethasone (Sigma), 0.5 mM isobutyl-methylxanthine (Sigma, 410957), and 10 μg/ml indomethacin (Sigma, 17378) for 23 days. The induction medium was changed every 3 days. Adipogenesis was assessed by staining with Oil Red O (Sigma, O0625). We captured the staining images with a microscope, BZ-8000 (Keyence).

Results {#sec013}
=======

Establishment of cell lines of human dental pulp stem cells transduced with CDK4^R24C^, Cyclin D1, and TERT {#sec014}
-----------------------------------------------------------------------------------------------------------

We transduced EGFP or human CDK4, Cyclin D1, and TERT into primary human dental pulp stem cells using retroviruses. We monitored the gene delivery efficiency of the retroviruses in the dental pulp stem cells using the recombinant retrovirus QCXIN-EGFP as a control. We estimated that the transduction of these genes into the dental pulp stem cells by retroviruses had an efficiency of approximately 50% ([Fig 1](#pone.0229996.g001){ref-type="fig"}, middle panels). Due to the presence of a neomycin-resistance gene downstream of QCXIN-EGFP, we performed selection using G418 antibiotics to purify the EGFP-expressing cells. The surviving cells selected by treatment with 1 mg/mL G418 were almost all positive for EGFP expression ([Fig 1](#pone.0229996.g001){ref-type="fig"}, lower panels), indicating that antibiotic selection worked properly. To evaluate the potential toxicity of these genes in human dental pulp cells, we compared the cell morphologies of the recombinant cells with those of primary cells. Although the recombinant cells' sizes were relatively smaller in K4D, K4DT, and TERT cells, the recombinant cells had a similar morphology to WT cells ([Fig 2](#pone.0229996.g002){ref-type="fig"}), indicating that transduction of human CDK4^R24C^, Cyclin D1, and TERT via retroviruses did not cause any toxicity in these cells.

![Detection of fluorescence in human dental pulp stem cells expressing QCXIN-EGFP.\
Differential interference contrast (DIC), fluorescence, and merged images of wild type human dental pulp cells as a control (no infection) (upper panel), QCXIN-EGFP infected human dental pulp cells (middle panels), and the surviving QCXIN-EGFP-infected human dental pulp cells selected by administration of 1000 μg/ml G418 (lower panels). Scale bar, 100 μm.](pone.0229996.g001){#pone.0229996.g001}

![The morphologies of wild type, K4D, K4DT, and TERT cells.\
Left panels show high magnification of the boxed regions in the right panels. Scale bar, 100 μm.](pone.0229996.g002){#pone.0229996.g002}

Detection of the genomic expression cassettes with PCR and detection of protein expression {#sec015}
------------------------------------------------------------------------------------------

To monitor the genomic insertion of exogenous genes, we performed PCR using genomic DNA extracted from EGFP, WT, K4D, K4DT, and TERT cells. The amplification products specific to the Cyclin D1, CDK4, and TERT expression cassettes were detected with expected ratios ([Fig 3A](#pone.0229996.g003){ref-type="fig"}), indicating that the expression cassettes were integrated into the cells. The results of TSC2 PCR amplification as a control showed that all genomic DNA produced sufficient amplification products, indicating that the recovery of genomic DNA and the amplification reaction worked properly. Furthermore, we carried out western blotting to detect the expression of Cyclin D1 and CDK4 proteins with specific antibodies. K4D and K4DT cells showed specific bands at the expected molecular weight, whereas WT showed a weak signal, which could be attributed to endogenous dental pulp stem cell-derived Cyclin D1 and CDK4 proteins ([Fig 3B](#pone.0229996.g003){ref-type="fig"}). Taken together, these data showed that the exogenous genes were inserted into the genomic DNA of human dental pulp stem cells and that functional proteins were produced by retroviral transduction.

![Detection of genomic cassette and protein expression in the retrovirus-infected human dental pulp cells.\
(A) PCR detection of CDK4, Cyclin D1, and TERT expression cassettes in the genomic DNA of EGFP, wild type (WT), K4D, and K4DT cells. PCR products from Tuberous sclerosis type 2 (TSC2) were used as an internal control. (B) Western blot analysis of wild type, K4D, and K4DT cells. The results obtained from anti-Cyclin D1, anti-CDK4, and anti-αtubulin antibody staining are shown.](pone.0229996.g003){#pone.0229996.g003}

K4DT cells continued to proliferate without cellular senescence {#sec016}
---------------------------------------------------------------

We compared proliferation of the established cells with or without transgenes. At the beginning, a specific number (5 x 10^4^ cells/35 mm diameter dish) of WT, K4D, and K4DT cells were seeded. The K4D and K4DT cells showed an increase in cell growth speed compared to WT cells ([Fig 4A](#pone.0229996.g004){ref-type="fig"}). The K4DT cells did not exhibit a decrease in cell proliferation, whereas K4D cells showed slower rates of proliferation at around passage 4. Furthermore, the WT and K4D cells showed enlarged cytoplasm, and the cells stained positively for senescence-associated beta-galactosidase (SA-β-Gal) at passage 7 ([Fig 4B](#pone.0229996.g004){ref-type="fig"}, upper and middle panels), indicating the presence of cellular senescence in WT and K4D cells. However, the K4DT cells showed no morphological changes and did not stain positively for SA-β-Gal ([Fig 4B](#pone.0229996.g004){ref-type="fig"}, lower panel). These results indicate that, although the expression of CDK4^R24C^ and Cyclin D1 induces dramatically enhanced cell proliferation speed until senescence at an early passage, co-expression of these genes is not enough to immortalize human dental pulp stem cells. We therefore concluded that the combined expression of CDK4^R24C^, Cyclin D1, and TERT allowed us to efficiently establish immortalized cells from human dental pulp cells.

![Growth curve of the cell proliferation of wild type, K4D, K4DT cells.\
(A) Cell growth and sequential passaging of wild type, K4D, and K4DT cells. Cell growth is represented by the cumulative population doubling value. (B) Detection of senescent cells in wild type, K4D, and K4DT cells at passage 7 by SA-beta-Gal staining. The arrows indicate positive blue staining, denoting cellular senescence. Scale bar, 50 μm.](pone.0229996.g004){#pone.0229996.g004}

Cell cycle assay {#sec017}
----------------

To compare the cell cycle distribution of cells, we performed cell cycle analysis of WT, K4D, and K4DT cells at passage 2. We compared the percentages of cells in each phase of the cell cycle. K4D and K4DT cells showed similar cell cycle profiles as WT cells, with a small fraction of S phase cells ([Fig 5A](#pone.0229996.g005){ref-type="fig"}). We also used six samples from each group to evaluate the potential effect of cell cycle stages. Both K4D and K4DT cells showed a significant decrease in the ratio of G0/G1 phase and an increase in the ratio of G2/M phase compared to WT cells ([Fig 5B](#pone.0229996.g005){ref-type="fig"}). These results indicated that cell proliferation was accelerated by the expression of mutant CDK4 and Cyclin D1.

![Cell cycle analysis of wild type, K4D, K4DT cells.\
(A) Cell cycle histogram of representative results obtained from wild type, K4D, and K4DT cells using the Muse Cell Cycle kit and the Muse Cell Analyzer. (B) The representative data of each experimental group were listed. Data are presented as the mean ± standard error of the ratio of each cell cycle stage (n = 6). We used the Steel-Dwass method. \*p \< 0.05, \*\*p \< 0.01.](pone.0229996.g005){#pone.0229996.g005}

Karyotype analysis {#sec018}
------------------

We evaluated the chromosomal karyotype of K4DT cells. To obtain the chromosome number, we evaluated 50 mitotic cells. The results showed that K4DT cells displayed a chromosome number of 2n = 46, indicating that K4DT cells retained the original number of chromosomes (Fig [6A, 6B and 6C](#pone.0229996.g006){ref-type="fig"}). In G-banding analysis, two samples out of 20 mitotic cells exhibited a chromosomal abnormality, indicating that more than 90% of K4DT cell samples had normal G banding patterns of human chromosomes ([Fig 6D](#pone.0229996.g006){ref-type="fig"}).

![Karyotype analysis of immortalized human dental pulp stem cells, termed K4DT cells.\
(A) Metaphase chromosomes visualized by Giemsa staining. (B) Aligned chromosomes from K4DT cells. Sex chromosomes are indicated as X and Y. (C) Representative results of karyotype analysis of K4DT cells. (D) The representative percentage and number of metaphase chromosomes in K4DT cells by G banding analysis.](pone.0229996.g006){#pone.0229996.g006}

Characterization of immortalized human dental pulp stem cells {#sec019}
-------------------------------------------------------------

To determine whether our immortalized cells keep the original characteristic of dental pulp stem cells, the stemness and their differentiation abilities were assessed by using the K4DT cells at passage 8, 15, or 16. Flow cytometry analysis of the K4DT cells showed more than 70% expressed CD90, which is cell surface markers in mesenchymal stem cells, whereas less than 1.0% of the K4DT expressed CD45 or CD34, which is hematopoietic cell surface markers. The WT cells showed similar results that CD90 expression was positive, whereas CD45 and CD34 expression were negative ([Fig 7](#pone.0229996.g007){ref-type="fig"}). These data indicated that the K4DT cells keep the original cell surface markers. In addition, K4DT cells at passages 15 showed positive staining of calcified materials by Alizarin red S after 17 days of culture in the osteoinduction medium ([Fig 8A](#pone.0229996.g008){ref-type="fig"}). Furthermore, we performed the immunofluorescence staining with anti-osteocalcin antibody. Osteocalcin was used for the mature osteoblast differentiation marker due to encode a bone specific protein synthesized by osteoblast \[[@pone.0229996.ref020]\]. The K4DT cells after 25 days of culture in the osteoinduction medium showed the osteocalcin-positive expression cells, while the cells of culture in the normal medium showed negative ([Fig 8B](#pone.0229996.g008){ref-type="fig"}). The data indicated that K4DT cells have the potency to differentiate into osteoblasts. We also observed that the K4DT cells at passages 16 developed numerous lipid droplets stained with Oil Red O at 23 days after the cells were induced to differentiate in the adipoinduction medium ([Fig 9](#pone.0229996.g009){ref-type="fig"}). The data indicate that the K4DT cells have the differentiation ability to adipocytes. From these results, we concluded that our established immortalized human dental pulp stem cells preserved the expression of stemness associated markers and their multi-differentiability even after passages.

![Cell surface phenotype of wild type and K4DT cells by flow cytometric analysis.\
The wild type and K4DT cells were positive for mesenchymal stem cell markers (CD90) and negative for hematopoietic markers (CD34 and CD45) (pink area). Isotype-identical antibodies served as the controls (blue area).](pone.0229996.g007){#pone.0229996.g007}

![Osteogenic differentiation properties of wild type and K4DT cells.\
Representative Alizarin Red S staining (A) and immunostaining (B) with anti-osteocalcin antibody *(red)* and DAPI staining *(blue)* of wild type and K4DT cells. For the Alizarin Red S staining, cells were cultured in osteoinduction medium for 17 days; 25 days for the osteocalcin staining. Middle panels show high magnification of the boxed regions in the left panels. White arrows indicate the positive expression of osteocalcin.](pone.0229996.g008){#pone.0229996.g008}

![Adipogenic differentiation properties of wild type and K4DT cells.\
Representative Oil Red O staining of wild type and K4DT cells. For the Oil Red O staining, cells were cultured in adipoinduction medium for 23 days. Middle panels show high magnification of the boxed regions in upper panels.](pone.0229996.g009){#pone.0229996.g009}

Discussion {#sec020}
==========

In this study, by co-expressing mutated cyclin-dependent kinase 4 (CDK4^R24C^), Cyclin D1, and telomerase reverse transcriptase (TERT), we established a novel immortalized human dental pulp stem cell line, termed K4DT cells, which do not have major chromosomal abnormalities or a transformed phenotype. Analysis of cell proliferation over sequential passages showed that K4DT cell lines had a more accelerated proliferation speed than K4D cell lines and primary human dental pulp stem cells. During these experiments, K4DT cells showed continuous proliferation without affecting differentiation potential and signs of senescence. This result indicated that using a combination of CDK4^R24C^, Cyclin D1, and TERT efficiently immortalized human dental pulp stem cells.

Cellular stress activates the p16-Rb (retinoblastoma protein) pathway \[[@pone.0229996.ref021]\]. The p16 protein binds the Cyclin D1-CDK4 complex and inactivates its kinase activity, which inhibits endogenous CDK4, resulting in a slowdown of cell cycle turnover \[[@pone.0229996.ref017]\]. Although the overexpression of wild-type CDK4 sequesters p16, CDK4 alone does not completely suppress Rb, because its kinase activity is inhibited by p16. Overexpression of mutant CDK4 (CDK4^R24C^), which is not bound by p16, in cooperation with Cyclin D1 can phosphorylate and suppress Rb in the presence of high levels of p16 \[[@pone.0229996.ref017]\]. However, to immortalize some cell types in culture, in addition to inactivation of the p16-Rb pathway, the expression of TERT is required to prevent progressive telomere shortening \[[@pone.0229996.ref022]\]. Sasaki et al. showed that neither CDK4^R24C^ nor Cyclin D1 alone or in combination with TERT could efficiently immortalize primary human ovarian surface epithelium cells \[[@pone.0229996.ref014]\]. In fact, our present study showed that combining the expression of CDK4^R24C^ and Cyclin D1 is insufficient to immortalize human dental pulp stem cells, termed K4D. We therefore concluded that the combined expression of the three genes successfully immortalized human dental pulp stem cells. We believe that our established K4DT cell line has the advantage of being easy to handle, which should increase the reproducibility and save time and costs for the safety and quality control tests needed for universal dental pulp regeneration therapy.

A previous study showed that human pulp-derived cells can be immortalized with Simian Virus 40 T-antigen (SV40) \[[@pone.0229996.ref023]\]. Although SV40 is well known to be able to effectively immortalize most cell types by inactivating the p53 and Rb pathways and interacting with a wide range of cellular proteins \[[@pone.0229996.ref024]\], the expression of SV40 frequently leads to chromosomal abnormalities and polyploidy in transformed human cells \[[@pone.0229996.ref025]--[@pone.0229996.ref027]\]. Our established immortalized human dental pulp stem cells showed no change in chromosome number, 46+XY. These results indicated that the K4DT immortalization method, which uses co-expression of CDK4^R24C^, Cyclin D1, and TERT, is better able to preserve the original nature of dental pulp stem cells without chromosomal instability compared to other immortalization methods, such as the use of SV40. However, in the G-banding analysis, we noted chromosomal aberrations in two out of 20 mitotic cells. We previously showed that 6.5% of cells exhibited abnormal chromosome patterns, even in wild type pig embryonic fibroblasts \[[@pone.0229996.ref026]\]. Therefore, there is a possibility that the \~10% observed chromosome abnormalities could be an artifact caused by sample preparation for chromosome analysis. On the other hand, immortalization driven by the expression of TERT alone was recently reported in cell types related to the dental field, including dental pulp cells \[[@pone.0229996.ref028],[@pone.0229996.ref029]\], human deciduous tooth dental pulp cells \[[@pone.0229996.ref030]\], and gingival fibroblasts \[[@pone.0229996.ref031]\]. Although we also tried to obtain immortalized dental pulp stem cells through the expression of TERT alone, we were unable to, even after confirming the successful integration of TERT into cells by PCR. Dental pulp stem cells expressing TERT alone stopped proliferating soon after expanding into new plates for further analysis assays, whereas K4D and K4DT cells showed constant proliferation. We used the pCLXSH-TERT plasmid that utilizes the viral LTR promoter for TERT expression, whereas others reported that immortalized dental pulp cells using TERT could be generated using the pQCXIP plasmid \[[@pone.0229996.ref032]\]. There is a possibility that dental pulp stem cells expressing TERT alone using the CMV promoter, which is stronger than the LTR promoter, or changing culture conditions that stimulate the stress signaling pathway \[[@pone.0229996.ref033]\] might promote continuous proliferation in cells transformed with TERT alone.

We performed flow cytometric analysis and the differentiation experiments used as methods for the identification and characterization of dental pulp stem cells \[[@pone.0229996.ref034]\], and observed our established immortalized human dental pulp stem cells, K4DT cells maintained its original stemness characteristics without affecting differentiation potential. The results suggest that co-expression of CDK4^R24C^, Cyclin D1, and TERT retain the original differentiation abilities of human dental pulp cells even though the cell proliferation was accelerated. Shiomi et al. reported that the co-expression of these three genes keeps the original cellular differentiation ability of human myogenic cells \[[@pone.0229996.ref017]\]. Our present results in differentiation experiments exhibited higher differentiation potential in the K4DT cells compared to that in primary human dental pulp stem cells, termed WT cells for both osteogenesis and adipogenesis. In these experiments, we used the WT cells at passage 8, which is passage number the cells have exhibited slower rates of cell proliferation as shown in [Fig 4A](#pone.0229996.g004){ref-type="fig"}. Therefore, the exact mechanism of the higher differentiation potential in K4DT cells has been unknown, the differentiation potential in K4DT cells might be due to keep the differentiation-inducing condition as primary human dental pulp stem cells in the early passages.

Conclusion {#sec021}
==========

We established novel human dental pulp stem cell lines without major chromosomal abnormalities or a transformed phenotype and losing their original characteristics by co-expressing mutant CDK4, Cyclin D1, and TERT. Our experimental results will contribute to the reduction of the therapeutic cost of pulp regeneration.
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======================

###### No crop gel images of the PCR amplifications of [Fig 3A](#pone.0229996.g003){ref-type="fig"}.

The corresponding area of the gel images were indicated by white rectangle.

(TIFF)

###### 

Click here for additional data file.

###### No crop blot images of the western blots of [Fig 3B](#pone.0229996.g003){ref-type="fig"}.

The corresponding area of the gel images were indicated by white rectangle.

(TIFF)

###### 

Click here for additional data file.

We would like to thank Dr. Akira Ishisaki (Iwate Medical University) for his technical help and fruitful advice.

10.1371/journal.pone.0229996.r001

Decision Letter 0

Papaccio

Gianpaolo

Academic Editor

© 2020 Gianpaolo Papaccio

2020

Gianpaolo Papaccio

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

7 Jan 2020

PONE-D-19-34813

Efficient immortalization of human dental pulp stem cells with expression of cell cycle regulators with intact chromosomal condition

PLOS ONE

Dear Orimoto,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

This study is of potential interest. but preliminary. As the reviewers specified the Authors must prove that cells do not die for senescence and keep their differentiating properties. To do so they must prove that after several passage they express antigens and are alive as well as that they are still capable to differentiate into osteogenic and adipogenic lineages.

We would appreciate receiving your revised manuscript by Feb 21 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Gianpaolo Papaccio, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

4\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

5\. Please ensure that you refer to Figure 5 in your text as, if accepted, production will need this reference to link the reader to the figure.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this paper authors established a novel immortalized dental pulp stem cell line by co-expressing a mutant cyclin-dependent kinase 4 (CDK4 R24C ), Cyclin D1, and telomerase reverse transcriptase (TERT). They concluded that the established K4DT cell line has the advantage of being easy to handle, resulting useful in dental pulp regeneration therapy.

The concept is interesting, but it represents only a preliminary study. The authors should test the characteristic of the new generated cell line, such as the stemness and the ability to differentiate at least in osteogenic lineage. For these reasons, the conclusions are not supported by data.

Reviewer \#2: In this manuscript the Authors describe a new immortalized cell line obtained from dental pulp stem cells infected with retrovirus carrying the genes for a mutant cyclin-dependent kinase 4 (CDK4R24C), Cyclin D1, and telomerase reverse transcriptase (TERT). The Authors showed that such cell line have a normal karyotype and do not go in senescence after few passages. The Authors propose this cell line as a new tool to study dental pulp stem cells based regeneration protocols. The work is interesting and the experiments are clearly performed, however there are few concerns that need to be addressed a s follow:

In order to be used as a tool for regeneration experiments it not sufficient to prove that the cells do not go in senescence, the author should also prove that the cells keep their differentiation properties, so they should allow the cells to grow for few passages and then show that they are still able to differentiate toward at least osteogenic and adipogenic phenotype (just as a proof of concept).

Dental pulp stem cells have been described to express different markers (see as an example "Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev Rep. 2011 Sep;7(3):608-15. doi: 10.1007/s12015-011-9235-9.) the Author should show that the expression of stemness associated markers is not lost after passages.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229996.r002

Author response to Decision Letter 0

10 Feb 2020

Revision summary

We would like to submit our revised version of our manuscript, which entitled "Efficient immortalization of human dental pulp stem cells with expression of cell cycle regulators with the intact chromosomal condition". All comments obtained from the reviewers were quite productive to improve our manuscript. We will list all comments and corresponding change listed below with point by point style. Furthermore, we will submit our revised manuscript with changes highlighted. In this round of revisions, we performed flow cytometric analysis and the differentiation experiments to test the characteristic of our generated cell line. We showed that our established immortalized human dental pulp stem cells preserved the expression of stemness associated markers and their differentiation properties even after passages. As we carried out our best efforts to satisfy the comments, we are glad to finish up the additional task, if it is essential for the acceptance of the manuscript.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

We performed double-check the formatting style of the PLoS One, and re-formatted the entire manuscript. Now, we hope that our modification of the manuscript style would be satisfactory to the comments.

2\. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study\'s minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see <http://journals.plos.org/plosone/s/data-availability>.

Upon re-submitting your revised manuscript, please upload your study's minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Based on the instruction, we included all experimental data used to the conclusions drawn in our manuscript. The data upload would be satisfactory to the comments from the journal office.

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.

Based on the instruction, we uploaded full range blots and gel images as Supplementary Figures.

4\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

Based on the instruction, the corresponding author create a new ORCID iD.

5\. Please ensure that you refer to Figure 5 in your text as, if accepted, production will need this reference to link the reader to the figure.

Based on the instruction, we included Figure 5 in our manuscript to allow the reader to link the figure. Thank you for the suggestion.

Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this paper authors established a novel immortalized dental pulp stem cell line by co-expressing a mutant cyclin-dependent kinase 4 (CDK4 R24C ), Cyclin D1, and telomerase reverse transcriptase (TERT). They concluded that the established K4DT cell line has the advantage of being easy to handle, resulting useful in dental pulp regeneration therapy.

The concept is interesting, but it represents only a preliminary study. The authors should test the characteristic of the new generated cell line, such as the stemness and the ability to differentiate at least in osteogenic lineage. For these reasons, the conclusions are not supported by data.

We appreciate very much to summarize the outline of our publication. Based on the comments, to test the characteristic of our generated cell line, termed K4DT cells, we performed flow cytometric analysis and the differentiation experiments. As a result, flow cytometry analysis of K4DT cells showed the high expression of the common stem cell markers in mesenchymal stem cell, CD90, and low expression of hematopoietic markers, CD34 and CD45, similar to the results observed in wild type cells. In the differentiation experiments, we tested the ability to differentiate in the osteogenic and adipogenic lineage. The K4DT cells were differentiated into osteoblasts immunostained with anti-osteocalcin antibody and showed marked mineralization by Alizarin Red S staining. K4DT cells also differentiated adipocytes and showed positive staining of numerous oil droplets by Oil red O.

Our data suggest that our established cell line maintained its original stemness characteristics without affecting differentiation potential.

To report the results described above, we involved new figures (Figure 7, 8, and 9 in the revised manuscript) and corresponding descriptions in the section of Materials and Methods (lines 157-183), Results (lines 248-268), and Discussion (lines 323-336).

Reviewer \#2: In this manuscript the Authors describe a new immortalized cell line obtained from dental pulp stem cells infected with retrovirus carrying the genes for a mutant cyclin-dependent kinase 4 (CDK4R24C), Cyclin D1, and telomerase reverse transcriptase (TERT). The Authors showed that such cell line have a normal karyotype and do not go in senescence after few passages. The Authors propose this cell line as a new tool to study dental pulp stem cells based regeneration protocols. The work is interesting and the experiments are clearly performed, however there are few concerns that need to be addressed a s follow:

In order to be used as a tool for regeneration experiments it not sufficient to prove that the cells do not go in senescence, the author should also prove that the cells keep their differentiation properties, so they should allow the cells to grow for few passages and then show that they are still able to differentiate toward at least osteogenic and adipogenic phenotype (just as a proof of concept).

Dental pulp stem cells have been described to express different markers (see as an example "Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev Rep. 2011 Sep;7(3):608-15. doi: 10.1007/s12015-011-9235-9.) the Author should show that the expression of stemness associated markers is not lost after passages.

We appreciate very much to summarize the outline of our publication and for the critical and productive comments to our publication. Based on the suggestion, to determine whether our immortalized cells, termed K4DT cells, keep the original characteristic of dental pulp stem cells, the stemness and their differentiation abilities were assessed by using the K4DT cells at passage 8, 15, or 16. As described in the responses to the Reviewer's comment \#1, flow cytometry analysis of K4DT cells at passage 8 showed the high expression of the common stem cell markers in mesenchymal stem cell, CD90 and low expression of hematopoietic markers, CD34 and CD45, similar to the results observed in wild type cells. In addition, we studied their differentiation abilities for osteogenesis and adipogenesis by using the K4DT cells at passage15 and 16. As a result, we observed that the K4DT cells differentiated into osteoblasts and adipocytes in each differentiation medium containing differentiation inducers. K4DT cells at passages 15 after approximately 3 months that started cell culture showed positive staining of calcified materials by Alizarin red S after 17 days. The K4DT cells also differentiated into osteoblasts immunostained with anti-osteocalcin antibody after 25 days. After 23 days of culture with adipoinduction medium, the K4DT at passages 16 developed numerous lipid droplets stained with Oil Red O. These results indicated that our established immortalized human dental pulp stem cells preserved the expression of stemness associated markers and their differentiation properties even after passages.

To report the results described above, we involved new figures (Figure 7, 8, and 9 in the revised manuscript) and corresponding descriptions in the section of Materials and Methods (lines 157-183), Results (lines 248-268), and Discussion (lines 323-336).
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Gianpaolo Papaccio

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

19 Feb 2020

PONE-D-19-34813R1

Efficient immortalization of human dental pulp stem cells with expression of cell cycle regulators with the intact chromosomal condition

PLOS ONE

Dear Orimoto,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

The paper has been improved but requires some minor amendments as specified below.

==============================

We would appreciate receiving your revised manuscript by Apr 04 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Gianpaolo Papaccio, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The manuscript is partially improved. Actually the Authors must add either in the Introduction and in the Discussion Sections some paragraphs regarding the osteogenic differentiation that DPSCs spontaneously undergo, citing the following previous literature: Clin Sci. 131, Issue 8, 2017, Pages 699-713 regarding the capability of DPSCs to build a human bone tissue as well as J cell Physiol 2013, 228, pp 1149/53 regarding osteocalcin.

Moreover they must add some info regarding the methods previously raised citing Stem Cell Rev rep 2011, 7: 608/15.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: The Authors have adressed the comments raised by this reviewer. The manuscriptresults greatly improved.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229996.r004
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February 20, 2020

Editorial Office

PLOS ONE

Dear Professor Gianpaolo Papaccio

We have attached our revised manuscript (PONE-D-19-34813R1) file entitled ': Efficient immortalization of human dental pulp stem cells with expression of cell cycle regulators with the intact chromosomal condition.' We appreciate your invitation to submit a revised manuscript and have provided an improved manuscript. We also provide responses for Additional Editor Comments. Furthermore, we will submit our revised manuscript with changes highlighted. As we carried out our best efforts to satisfy the comments, we are happy to finish up the additional task, if it is essential for the acceptance of the manuscript.

Additional Editor Comments (if provided):

The manuscript is partially improved. Actually the Authors must add either in the Introduction and in the Discussion Sections some paragraphs regarding the osteogenic differentiation that DPSCs spontaneously undergo, citing the following previous literature: Clin Sci. 131, Issue 8, 2017, Pages 699-713 regarding the capability of DPSCs to build a human bone tissue as well as J cell Physiol 2013, 228, pp 1149/53 regarding osteocalcin.

We appreciate very much for the supportive comments to our publication. We agree with this comment that we must add these references. As suggested, we have added two references as suggested, and have improved the corresponding manuscript at line 49-51 and lines 261-262.

Moreover they must add some info regarding the methods previously raised citing Stem Cell Rev rep 2011, 7: 608/15.

Thank you for your suggestion. As suggested, we included the reference in the section of Discussion and improved the corresponding manuscript at line 326-329.

We hope that the revised manuscript is now acceptable for publication in Plos one. If you require any further information, please do not hesitate to contact me.

Sincerely,

Ai Orimoto

Ai Orimoto, DDS, Ph. D.

Graduate School of Science and Engineering, Iwate University,

4-3-5, Ueda, Morioka, Iwate, 020-8551, Japan

TEL: 81-19-621-6375

E-mail: orimoto@ iwate-u.ac.jp

10.1371/journal.pone.0229996.r005
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Efficient immortalization of human dental pulp stem cells with expression of cell cycle regulators with the intact chromosomal condition

PONE-D-19-34813R2

Dear Dr. Orimoto,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Gianpaolo Papaccio, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The Authors answered to all the previous comments.

Reviewers\' comments:

10.1371/journal.pone.0229996.r006
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PONE-D-19-34813R2

Efficient immortalization of human dental pulp stem cells with expression of cell cycle regulators with the intact chromosomal condition

Dear Dr. Orimoto:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Gianpaolo Papaccio

Academic Editor

PLOS ONE
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